Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Thrombin activatable fibrinolysis inhibitor (TAFI) is a plasma enzyme that plays a crucial role in regulating the balance between coagulation and fibrinolysis. It circulates as an inactive zymogen and is activated by thrombin or plasmin. TAFIa functions as a metallocarboxypeptidase that removes C-terminal lysine or arginine residues from peptide substrates, primarily attenuating fibrinolysis. Elevated levels or activity are associated with increased risk for thrombotic diseases. TAFI/TAFIa also participates in inflammatory processes.
Inhibition of TAFI activation or enzymatic activity, leading to enhanced fibrinolysis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Thrombin Activatable Fibrinolysis Inhibitor (TAFI).